[144] Adaptimmune Therapeutics plc American SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Adaptimmune Therapeutics plc (ADAP) reports a proposed sale of 16,000 American Depositary Shares (ADS) with an aggregate market value of $942.40, to be sold on or about 09/02/2025 on Nasdaq. The filing shows the ADS were acquired in three open-market purchases: 5,500 on 06/29/2020, 4,000 on 12/14/2020, and 6,500 on 05/20/2022, all paid in cash. The filing states there were no securities sold in the past three months by the selling person. Several identifying fields for the filer and issuer (names, CIK) are blank in the provided content.

Positive

• Clear acquisition history provided for the 16,000 ADS showing dates and cash payments
• No sales in the past three months by the selling person, as reported

Negative

• Key identification fields are blank or not provided in the supplied content (filer name/CIK and issuer name), limiting assessment
• Aggregate market value is very small ($942.40) relative to the reported outstanding shares, suggesting immateriality

Insights

Securities Analyst

TL;DR Routine Form 144 disclosing a small-volume proposed ADS sale on Nasdaq; limited market impact expected.

The filing discloses a proposed sale of 16,000 ADS valued at $942.40, originating from open-market purchases across 2020 and 2022. Given the very small aggregate value relative to the issuer's outstanding ADS count (256,032,610), the transaction appears immaterial to market capitalization. The absence of recent sales in the prior three months reduces concerns about an immediate larger disposition. However, key identifying information for the filer and issuer is not present in the provided content, limiting the ability to assess insider status or potential signaling effects.

Corporate Governance Expert

TL;DR Disclosure meets Rule 144 mechanics but lacks full identification details in the provided extract.

The form documents the seller's representation about lack of material non-public information and records acquisition dates and payment method (cash), which aligns with compliance expectations under Rule 144. The filing indicates the seller did not aggregate any sales in the last three months. Missing filer and issuer identifying fields in the supplied content constrain evaluation of whether this sale is by an affiliate or non-affiliate, which is material for governance and disclosure interpretation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Rowan Dartington 3rd and 4th Floor, Temple Point Redcliffe Way Bristol X0 BS1 6NJ	16000	942.40	256032610	09/02/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	06/29/2020	Open market purchase	Not known			5500	06/29/2020	Cash
American Depositary Shares	12/14/2020	Open market purchase	Not known			4000	12/14/2020	Cash
American Depositary Shares	05/20/2022	Open market purchase	Not known			6500	05/20/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for ADAP report?

The form reports a proposed sale of 16,000 ADS of Adaptimmune Therapeutics plc with an aggregate market value of $942.40 to be sold on or about 09/02/2025 on Nasdaq.

When were the ADS being sold originally acquired?

The ADS were acquired in open-market purchases on 06/29/2020 (5,500 ADS), 12/14/2020 (4,000 ADS), and 05/20/2022 (6,500 ADS), paid in cash.

Does the filing report any sales in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months by the selling person.

On which exchange is the sale expected to occur?

The proposed sale is expected to occur on Nasdaq.

Is there identifying information for the filer and issuer in the document?

In the provided content, the filer and issuer identifying fields (names, CIK) are not populated, which limits further assessment.